NYSE: GSKGsk PLC Stock
$34.38-0.84 (-2.39%)
Updated Mar 24, 2023
GSK Price
$34.38
Fair Value Price
N/A
Market Cap
$69.21B
52 Week Low
$28.47
52 Week High
$58.71
P/E
3.84x
P/B
5.42x
P/S
2x
PEG
N/A
Dividend Yield
4.07%
Revenue
$35.33B
Earnings
$18.02B
Gross Margin
67.4%
Operating Margin
56.41%
Profit Margin
51%
Debt to Equity
4.72
Operating Cash Flow
$9B
Beta
0.54
Next Earnings
Apr 26, 2023
Ex-Dividend
Feb 23, 2023
Next Dividend
Apr 13, 2023
GSK Overview
GSK plc is a pharmaceutical company operating in several therapeutic classes, including respiratory, oncology, and antiviral. It also offers vaccines and consumer healthcare products. Known as GlaxoSmithKline plc until 2022, the company was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. It is headquartered in London, UK.
Zen Score
–
Industry Average (44)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GSK scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GSK is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
GSK is good value based on its earnings relative to its share price (3.84x), compared to the US market average (21.37x)
P/E vs Market Valuation
GSK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more GSK due diligence checks available for Premium users.
Be the first to know about important GSK news, forecast changes, insider trades & much more!
GSK News
Valuation
GSK price to earnings (PE)
For valuing profitable companies with steady earnings
Company
3.84x
Industry
26.79x
Market
21.37x
GSK is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
GSK is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
GSK price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.42x
Industry
4.89x
GSK is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GSK's financial health
Profit margin
Revenue
$8.9B
Net Income
$2.4B
Profit Margin
27.1%
GSK's Earnings (EBIT) of $19.93B... subscribe to Premium to read more.
Interest Coverage Financials
GSK's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$72.5B
Liabilities
$60.3B
Debt to equity
4.72
GSK's short-term liabilities ($27.48B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GSK's long-term liabilities ($32.82B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GSK's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GSK's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$2.3B
Investing
-$650.6M
Financing
-$1.6B
GSK's operating cash flow ($8.92B)... subscribe to Premium to read more.
Debt Coverage Financials
GSK vs General Drug Manufacturer Stocks
Gsk Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.